Tivic Health Systems, Inc. is a medical technology company focused on developing innovative solutions for chronic conditions affecting the upper respiratory tract
The company specializes in advanced neuromodulation therapies, which leverage electrical stimulation to address symptoms associated with conditions such as rhinitis and sinusitis. By utilizing its proprietary technology, Tivic Health aims to enhance patient quality of life through non-invasive treatment options that offer an alternative to traditional medication. Their commitment to research and development positions them at the forefront of transforming how patients manage their health.
Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation’s impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to current, more invasive treatment options.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company’s issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the Company’s Compliance Plan, as presented to Nasdaq on February 18, 2025.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food & Drug Administration approval and commercialization of Tivic’s non-invasive cervical vagus nerve stimulation (VNS) device.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies.
